These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 990007)

  • 1. Assessment of the thrombolytic effect of low urokinase concentrations.
    Matsuo O; Mihara H; Rokushima Y
    Nihon Ketsueki Gakkai Zasshi; 1976 Jun; 39(3):298-305. PubMed ID: 990007
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experimental studies on the mode and amount of urokinase administration in thrombolytic therapy (author's transl)].
    Matsuo O; Mihara H
    Rinsho Ketsueki; 1977 Sep; 18(9):1097-101. PubMed ID: 592505
    [No Abstract]   [Full Text] [Related]  

  • 5. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
    Maksimenko AV
    Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of thrombolytic agents.
    Wolf P
    N Engl J Med; 1980 Apr; 302(14):812. PubMed ID: 6444451
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
    Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
    Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
    [No Abstract]   [Full Text] [Related]  

  • 8. [New technics in the treatment of the coronary insufficiency. Conclusions].
    Rovelli F
    G Ital Cardiol; 1983; 13(4):357-9. PubMed ID: 6224718
    [No Abstract]   [Full Text] [Related]  

  • 9. How should intravenous thrombolytic agents for acute myocardial infarction be selected?
    Topol EJ
    Cardiovasc Clin; 1990; 21(1):57-75; discussion 76-8. PubMed ID: 2143103
    [No Abstract]   [Full Text] [Related]  

  • 10. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
    Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tissue plasminogen activator].
    Matsuo O
    Rinsho Ketsueki; 1984 Jul; 25(7):1004-10. PubMed ID: 6542154
    [No Abstract]   [Full Text] [Related]  

  • 12. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
    Gurewich V
    Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
    [No Abstract]   [Full Text] [Related]  

  • 13. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
    Bode C; Eberle T; Runge M; Haber E; Kübler W
    Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
    [No Abstract]   [Full Text] [Related]  

  • 14. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
    Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
    Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
    Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of thrombolysis.
    Sell JJ; Rupp FW; Telepak RJ
    West J Med; 1996; 165(1-2):53. PubMed ID: 8855686
    [No Abstract]   [Full Text] [Related]  

  • 18. Local thrombolytic therapy: bridging the "generation gap".
    Becker GJ
    AJR Am J Roentgenol; 1983 Feb; 140(2):403-5. PubMed ID: 6600365
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of oral urokinase and its clinical application.
    Abe T; Kazama M; Naito I; Kinoshita T; Sasaki K
    New Istanbul Contrib Clin Sci; 1982; 13(3):161-70. PubMed ID: 6760114
    [No Abstract]   [Full Text] [Related]  

  • 20. Vasodilation, fibrinolysis, and thrombolysis with intraarterial infusion of urokinase in the canine superior mesenteric artery.
    Gurll N; Zinner MJ; Turtinen L; Reynolds DG
    Gastroenterology; 1978 Sep; 75(3):425-31. PubMed ID: 98390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.